Loading patent…
AssigneesThe General Hospital Corporation, President and Fellows of Harvard College, The Brigham and Womens's Hospital, Inc.
InventorsRaaj S. Mehta, Curtis Huttenhower, Andrew T. Chan, Jared R. Mayers, Emily Balskus
Estimating the term…
The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.
A method of determining whether a patient diagnosed with inflammatory bowel disease (IBD) will respond to 5-ASA therapy, the method comprising:
A method for treating a patient having IBD comprising administering to the patient a biologic in an amount effective to treat IBD when a stool sample from the patient comprises microbial acetyltransferase genes capable of converting 5-ASA to N-acetyl 5-ASA.
A method for treating a patient having IBD comprising administering to the patient an immunomodulator in an amount effective to treat IBD when a stool sample from the patient comprises microbial acetyltransferase genes capable of converting 5-ASA to N-acetyl 5-ASA.
A method for treating a patient having IBD comprising administering to the patient 5-aminosalicylic acid (5-ASA) in an amount effective to treat IBD when microbial acetyltransferase genes are not present in a stool sample from the patient.
Dependencies are inferred from the claim text.